Last updated: 3 September 2024 at 7:12pm EST

Catherine Szyman Net Worth




The estimated Net Worth of Catherine M. Szyman is at least $13 millió dollars as of 3 May 2024. Ms. Szyman owns over 5,796 units of Edwards Lifesciences Corp stock worth over $3,345,479 and over the last 10 years she sold EW stock worth over $6,858,666. In addition, she makes $2,794,690 as Corporate Vice President - Critical Care at Edwards Lifesciences Corp.

Ms. Szyman EW stock SEC Form 4 insiders trading

Catherine has made over 63 trades of the Edwards Lifesciences Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 5,796 units of EW stock worth $395,577 on 3 May 2024.

The largest trade she's ever made was exercising 80,308 units of Edwards Lifesciences Corp stock on 7 May 2023 worth over $2,660,604. On average, Catherine trades about 5,185 units every 27 days since 2015. As of 3 May 2024 she still owns at least 49,018 units of Edwards Lifesciences Corp stock.

You can see the complete history of Ms. Szyman stock trades at the bottom of the page.





Catherine Szyman biography

Catherine M. Szyman serves as Corporate Vice President - Critical Care of the Company. Ms. Szyman has been Corporate Vice President, Critical Care since 2015. Under her leadership, Edwards has experienced successful sales growth in the Critical Care business unit. Prior to 2015, she was employed for more than 20 years at Medtronic, LLC, where she served as its Senior Vice President and President of Medtronic’s global diabetes business from 2009 to 2014, overseeing research, development, operations, sales and marketing for Medtronic’s insulin infusion pumps and continuous glucose monitoring systems. Prior to that, she held a variety of leadership roles at Medtronic, including Senior Vice President of Corporate Strategy and Business Development, General Manager of Endovascular Innovations and Vice President of Finance for the Cardiovascular Business. Ms. Szyman currently serves on the boards of Endotronix, Octane OC and Inari Medical, Inc. and previously served on the boards of Tornier, Inspire Medical Systems, and the California Healthcare Institute.

What is the salary of Catherine Szyman?

As the Corporate Vice President - Critical Care of Edwards Lifesciences Corp, the total compensation of Catherine Szyman at Edwards Lifesciences Corp is $2,794,690. There are 4 executives at Edwards Lifesciences Corp getting paid more, with Michael Mussallem having the highest compensation of $11,521,000.



How old is Catherine Szyman?

Catherine Szyman is 63, she's been the Corporate Vice President - Critical Care of Edwards Lifesciences Corp since 2015. There are 6 older and 13 younger executives at Edwards Lifesciences Corp. The oldest executive at Edwards Lifesciences Corp is William Link, 74, who is the Independent Director.

What's Catherine Szyman's mailing address?

Catherine's mailing address filed with the SEC is ONE EDWARDS WAY, , IRVINE, CA, 92614.

Insiders trading at Edwards Lifesciences Corp

Over the last 21 years, insiders at Edwards Lifesciences Corp have traded over $94,964,396 worth of Edwards Lifesciences Corp stock and bought 47,398 units worth $3,992,090 . The most active insiders traders include Michael A Mussallem, Donald E Jr Bobo és Steven R Loranger. On average, Edwards Lifesciences Corp executives and independent directors trade stock every 8 days with the average trade being worth of $1,126,057. The most recent stock trade was executed by Donald E Jr Bobo on 11 September 2024, trading 5,000 units of EW stock currently worth $226,400.



What does Edwards Lifesciences Corp do?

edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.



Complete history of Ms. Szyman stock trades at Edwards Lifesciences Corp, Inari Medical és Outset Medical

Az érdekelt
Trans.
Tranzakció
Teljes ár
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $494,109
3 May 2024
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $1,727,250
13 Feb 2024
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $183,750
10 Oct 2023
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $183,750
8 Sep 2023
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $183,750
9 Aug 2023
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $183,750
7 Jul 2023
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $183,750
13 Jun 2023
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $2,660,604
7 May 2023
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $1,226,947
7 May 2022
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $509,184
3 May 2022
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $435,200
11 Apr 2022
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $435,200
14 Mar 2022
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $435,200
18 Feb 2022
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $217,600
14 Jan 2022
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $217,600
17 Dec 2021
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $217,600
18 Nov 2021
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $211,964
18 Oct 2021
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $211,964
8 Sep 2021
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $326,400
2 Aug 2021
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $76,009
15 Jun 2021
Catherine M. Szyman
CVP és Critical Care
Eladás $196,393
28 May 2021
Catherine M. Szyman
CVP és Critical Care
Eladás $448,307
25 May 2021
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $1,367,966
17 May 2021
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $75,541
7 May 2021
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $75,541
22 Apr 2021
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $75,541
15 Mar 2021
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $75,541
16 Feb 2021
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $75,541
15 Jan 2021
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $453,713
29 Oct 2020
Catherine M. Szyman
CVP és Critical Care
Eladás $175,962
13 Aug 2020
Catherine M. Szyman
CVP és Critical Care
Eladás $152,167
14 Jul 2020
Catherine M. Szyman
CVP és Critical Care
Eladás $236,603
16 Jun 2020
Catherine M. Szyman
CVP és Critical Care
Eladás $163,255
11 Jun 2020
Catherine M. Szyman
CVP és Critical Care
Eladás $237,362
14 May 2020
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $1,339,048
11 May 2020
Catherine M. Szyman
CVP és Critical Care
Eladás $242,072
16 Apr 2020
Catherine M. Szyman
CVP és Critical Care
Eladás $181,852
23 Mar 2020
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $167,150
18 Feb 2020
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $167,150
3 Feb 2020
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $167,150
16 Dec 2019
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $167,150
15 Nov 2019
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $167,150
25 Oct 2019
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $167,150
19 Sep 2019
Catherine M. Szyman
CVP és Critical Care
Eladás $156,732
30 Aug 2019
Catherine M. Szyman
CVP és Critical Care
Eladás $150,171
15 Aug 2019
Catherine M. Szyman
CVP és Critical Care
Eladás $283,716
15 Jul 2019
Catherine M. Szyman
CVP és Critical Care
Eladás $272,027
14 Jun 2019
Catherine M. Szyman
CVP és Critical Care
Eladás $262,254
15 May 2019
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $469,955
12 May 2019
Catherine M. Szyman
CVP és Critical Care
Eladás $283,008
15 Apr 2019
Catherine M. Szyman
CVP és Critical Care
Eladás $263,993
15 Mar 2019
Catherine M. Szyman
CVP és Critical Care
Eladás $259,925
21 Feb 2019
Catherine M. Szyman
CVP és Critical Care
Eladás $108,500
15 Jan 2019
Catherine M. Szyman
CVP és Critical Care
Eladás $113,862
14 Dec 2018
Catherine M. Szyman
CVP és Critical Care
Eladás $103,572
15 Nov 2018
Catherine M. Szyman
CVP és Critical Care
Eladás $99,848
15 Oct 2018
Catherine M. Szyman
CVP és Critical Care
Eladás $1,368,113
24 May 2018
Catherine M. Szyman
CVP és Critical Care
Opció Gyakorlat $1,277,164
16 May 2018
Catherine M. Szyman
CVP és Critical Care
Eladás $541,966
31 Jul 2017
Catherine M. Szyman
CVP és Critical Care
Eladás $557,007
29 Jun 2017
Catherine M. Szyman
CVP és Critical Care
Megvenni $1,073,744
30 Nov 2016
Catherine M. Szyman
CVP és Critical Care
Megvenni $1,073,744
30 Nov 2016
Catherine M. Szyman
Rendező
Megvenni $533,729
27 May 2020


Edwards Lifesciences Corp executives and stock owners

Edwards Lifesciences Corp executives and other stock owners filed with the SEC include: